German scientists have claimed to have suppressed the cause of the rare hemorrhage associated with the Oxford / AstraZeneca and Johnson & Johnson coronavirus vaccines and believe the jabs could be tweaked to actually stop the reaction from occurring. .
Rolf Marschalek, a professor at Goethe university in Frankfurt who has led the study of the rare condition since March, says his research shows that the problem lies with the adenovirus vectors used in the same vaccine to deliver the spike protein. of Sars-Cov-2 virus in the body.
The mechanism of delivery means that vaccines deliver spike protein to the cell nucleus rather than the cytosol fluid found inside the cell where the virus normally makes proteins, according to Marschalek and other scientists. preprint paper released on Wednesday.
Once inside the cell nucleus, some parts of the spike protein splice, or separate, form mutant versions, which do not bind to the cell membrane where the underlying vaccination occurs. Floating mutant proteins are instead secreted by body cells, triggering the bloodstream of nearly one in 100,000 people, according to Marschalek’s theory.
In contrast, mRNA -based vaccines, such as jabs made by BioNTech / Pfizer and Moderna, deliver the genetic material to the spike in the cell fluid and never penetrate the stem.
“When. . . The genes of the virus are in the trunk that they can create some problems, ”Marschalek told the Financial Times.
The bizarre blood reaction to the launch of the AstraZeneca and J&J shots was recorded in 309 of the 33m people who received AstraZeneca vaccine in the UK, causing 56 deaths. In Europe, at least 142 people have experienced a hemorrhage from 16m who receive the vaccine.
In response, the use of the AstraZeneca jab has been banned or suspended in more than a dozen countries. J&J began launching its vaccine in Europe with a warning on its brand in April after a slight delay due to concerns.
But Marschalek believes there is a straight-forward “way out” if vaccine developers can change the order of the spike protein to avoid it separating.
J&J has already contacted Marschalek’s lab to ask for guidance and is looking at ways to modify its vaccine to prevent mixing, he said.
The spike protein in the J&J shot is no more prone to “splicing” than the spike protein in the AstraZeneca jab, making the reaction less common, according to Marschalek. In the U.S., eight of the 7.4m who received a J&J shooting reported a rare reaction.
“[J&J] trying to optimize the vaccine now, “he said.” With the data at our fingertips we can let companies know how to change these sequences, coding for spike protein in a way that prevents unintended splice reactions. “
J&J says: “We support the ongoing research and analysis of this rare event as we work with medical experts and health authorities around the world. We look forward to reviewing and sharing the data as it becomes feasible. ”
Some scientists are wary that Marschalek’s theory is one of the majority, and more evidence is needed to substantiate his claims.
“There is evidence missing to show the cause of the chain from the splice… Of spike protein in thrombosis events,” said Johannes Oldenburg, professor of transfusion medicine at the university of Bonn. “This is another hypothesis. must be substantiated by experimental data. “
Marschalek said he presented the findings of his lab at the Paul-Ehrlich Institute of the German government and the country’s advisory body on vaccination and immunization.
“They were amazed at what we found out, because no one thought about the splice problem,” he said.